Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cosibelimab |
Synonyms | |
Therapy Description |
Cosibelimab (CK-301) is a human monoclonal antibody against PD-L1 (CD274), which may block immune checkpoint, lead to anti-tumor immune response (Ann Oncol. Oct 2019, Vol 30 (Suppl_5): v177). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cosibelimab | CK-301|CK 301|TG-1501|TG1501|TG 1501 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | Cosibelimab (CK-301) is a human monoclonal antibody against PD-L1 (CD274), which may block immune checkpoint, lead to anti-tumor immune response (Ann Oncol. Oct 2019, Vol 30 (Suppl_5): v177). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03778073 | Phase I | Cosibelimab | Study of TG-1501 in Subjects With Relapsed or Refractory Lymphoma | Terminated | USA | 0 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | POL | NZL | FRA | ESP | AUS | 4 |